These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20580618)

  • 1. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response.
    Chéramy M; Skoglund C; Johansson I; Ludvigsson J; Hampe CS; Casas R
    Clin Immunol; 2010 Oct; 137(1):31-40. PubMed ID: 20580618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
    Axelsson S; Chéramy M; Akerman L; Pihl M; Ludvigsson J; Casas R
    Diabetes Care; 2013 Nov; 36(11):3418-24. PubMed ID: 23863909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.
    Chéramy M; Hampe CS; Ludvigsson J; Casas R
    Clin Exp Immunol; 2013 Mar; 171(3):247-54. PubMed ID: 23379430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GAD autoantibody epitope pattern after GAD-alum treatment in children and adolescents with type 1 diabetes.
    Skoglund C; Chéramy M; Casas R; Ludvigsson J; Hampe CS
    Pediatr Diabetes; 2012 May; 13(3):244-50. PubMed ID: 21848927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
    Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
    J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
    Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
    Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
    Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
    N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of simultaneous vaccination with H1N1 and GAD-alum on GAD
    Tavira B; Cheramy M; Axelsson S; Åkerman L; Ludvigsson J; Casas R
    Diabetologia; 2017 Jul; 60(7):1276-1283. PubMed ID: 28357504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-lymphatic administration of GAD-alum in type 1 diabetes: long-term follow-up and effect of a late booster dose (the DIAGNODE Extension trial).
    Casas R; Dietrich F; Puente-Marin S; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
    Acta Diabetol; 2022 May; 59(5):687-696. PubMed ID: 35098372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
    Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
    Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
    Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
    Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
    Elding Larsson H; Lundgren M; Jonsdottir B; Cuthbertson D; Krischer J;
    Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
    Krause S; Landherr U; Agardh CD; Hausmann S; Link K; Hansen JM; Lynch KF; Powell M; Furmaniak J; Rees-Smith B; Bonifacio E; Ziegler AG; Lernmark A; Achenbach P
    Diabetes Care; 2014 Jun; 37(6):1675-80. PubMed ID: 24598244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
    Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
    Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
    Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
    Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality.
    Hawa MI; Fava D; Medici F; Deng YJ; Notkins AL; De Mattia G; Leslie RD
    Diabetes Care; 2000 Feb; 23(2):228-33. PubMed ID: 10868836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.
    Pihl M; Akerman L; Axelsson S; Chéramy M; Hjorth M; Mallone R; Ludvigsson J; Casas R
    Clin Exp Immunol; 2013 Jun; 172(3):394-402. PubMed ID: 23600827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
    Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
    Diabetes Metab Res Rev; 2022 Mar; 38(3):e3500. PubMed ID: 34611978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy with GAD in diabetes.
    Ludvigsson J
    Diabetes Metab Res Rev; 2009 May; 25(4):307-15. PubMed ID: 19267332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
    Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
    Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.